Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
作者信息
Jia Keren, Chen Yang, Sun Yu, Hu Yajie, Jiao Lei, Ma Jie, Yuan Jiajia, Qi Changsong, Li Yanyan, Gong Jifang, Gao Jing, Zhang Xiaotian, Li Jian, Zhang Cheng, Shen Lin
机构信息
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
出版信息
BMC Med. 2023 Sep 29;21(1):369. doi: 10.1186/s12916-023-03090-4.
Abstract
摘要
相似文献
1
Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.更正：多重免疫组化定义CLDN18.2阳性胃癌的肿瘤免疫微环境和免疫治疗结果。
BMC Med. 2023 Sep 29;21(1):369. doi: 10.1186/s12916-023-03090-4.
2
Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.多重免疫组化定义了 CLDN18.2 阳性胃癌的肿瘤免疫微环境和免疫治疗结果。
BMC Med. 2022 Jul 11;20(1):223. doi: 10.1186/s12916-022-02421-1.
3
CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.CLDN18.2 的表达及其对胃癌预后和免疫微环境的影响。
BMC Gastroenterol. 2023 Aug 16;23(1):283. doi: 10.1186/s12876-023-02924-y.
4
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.CLDN18.2 和 4-1BB 双特异性抗体 givastomig 通过 CLDN18.2 表达肿瘤靶向 T 细胞激活发挥抗肿瘤活性。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-006704.
5
Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.耦合CDH17和CLDN18标志物用于人胃癌的全面膜靶向检测。
Oncotarget. 2016 Sep 27;7(39):64168-64181. doi: 10.18632/oncotarget.11638.
6
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.ZL-1211 通过增强 ADCC 和激活 NK 细胞介导的炎症反应，在 Claudin18.2 高表达和低表达的胃癌模型中表现出强大的抗肿瘤活性。
Cancer Res Commun. 2022 Sep 7;2(9):937-950. doi: 10.1158/2767-9764.CRC-22-0216. eCollection 2022 Sep.
7
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.比较 Claudin 18.2 在日本胃腺癌患者原发肿瘤和淋巴结转移中的表达。
Jpn J Clin Oncol. 2019 Sep 1;49(9):870-876. doi: 10.1093/jjco/hyz068.
8
Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.与传统胃癌相比，甲胎蛋白产生型胃癌中claudin-18.2的表达降低。
J Gastrointest Oncol. 2022 Jun;13(3):1035-1045. doi: 10.21037/jgo-22-462.
9
Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens. Claudin18.2 表达与胃腺癌细胞学胸腔积液标本的临床病理特征：与组织标本的对比研究。
Cancer Cytopathol. 2023 Jun;131(6):365-372. doi: 10.1002/cncy.22688. Epub 2023 Feb 15.
10
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.Claudin18.2 特异性嵌合抗原受体工程化 T 细胞治疗胃癌。
J Natl Cancer Inst. 2019 Apr 1;111(4):409-418. doi: 10.1093/jnci/djy134.
引用本文的文献
1
Clinicopathological significance and prognostic values of claudin18.2 expression in solid tumors: a systematic review and meta-analysis.紧密连接蛋白18.2在实体瘤中的表达的临床病理意义及预后价值：一项系统评价与荟萃分析
Front Oncol. 2024 Nov 20;14:1453906. doi: 10.3389/fonc.2024.1453906. eCollection 2024.
本文引用的文献
1
Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.多重免疫组化定义了 CLDN18.2 阳性胃癌的肿瘤免疫微环境和免疫治疗结果。
BMC Med. 2022 Jul 11;20(1):223. doi: 10.1186/s12916-022-02421-1.
Zotero 插件